TR200002894T2 - L-Carnitine or an alkanoyl L-Carnitine and composition containing NADH and / or NADPH - Google Patents
L-Carnitine or an alkanoyl L-Carnitine and composition containing NADH and / or NADPHInfo
- Publication number
- TR200002894T2 TR200002894T2 TR2000/02894T TR200002894T TR200002894T2 TR 200002894 T2 TR200002894 T2 TR 200002894T2 TR 2000/02894 T TR2000/02894 T TR 2000/02894T TR 200002894 T TR200002894 T TR 200002894T TR 200002894 T2 TR200002894 T2 TR 200002894T2
- Authority
- TR
- Turkey
- Prior art keywords
- carnitine
- nadph
- alkanoyl
- composition containing
- containing nadh
- Prior art date
Links
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 title abstract 4
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 title abstract 2
- -1 alkanoyl L-Carnitine Chemical compound 0.000 title abstract 2
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 title abstract 2
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 title 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 abstract 1
- 235000005911 diet Nutrition 0.000 abstract 1
- 230000000378 dietary effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L-karnitin veya bir alkanoil L-karnitin veya bunlarin farmasötik olarak kabul edilebilir tuzu ve NADH ve/veya NADPH içeren, kronik yorgunluk sendromu ve Parkinson hastaliginin tedavisi için bir ilaç olarak ve yorucu fiziksel egzersizde bulunan kisiler veya kuvvetsiz denekler için bir diyet yardimcisi olarak yararli bir kompozisyon açiklanmaktadir.Useful as a medicine for the treatment of chronic fatigue syndrome and Parkinson's disease, including L-carnitine or an alkanoyl L-carnitine or their pharmaceutically acceptable salt and NADH and / or NADPH, and as a dietary aid for individuals or weak subjects in strenuous physical exercise. a composition is described.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT98RM000238A IT1299161B1 (en) | 1998-04-17 | 1998-04-17 | COMPOSITION INCLUDING L-CARNITINE OR AN ALCANOYL L-CARNITINE AND NADH AND / OR NADPH |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR200002894T2 true TR200002894T2 (en) | 2001-01-22 |
Family
ID=11405812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2000/02894T TR200002894T2 (en) | 1998-04-17 | 1999-04-14 | L-Carnitine or an alkanoyl L-Carnitine and composition containing NADH and / or NADPH |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1071424A1 (en) |
| JP (1) | JP2002512191A (en) |
| KR (1) | KR20010042765A (en) |
| CN (1) | CN1299283A (en) |
| AU (1) | AU750645B2 (en) |
| BR (1) | BR9909712A (en) |
| CA (1) | CA2328331A1 (en) |
| EE (1) | EE200000601A (en) |
| HU (1) | HUP0101914A3 (en) |
| IL (1) | IL139014A0 (en) |
| IS (1) | IS5663A (en) |
| IT (1) | IT1299161B1 (en) |
| NO (1) | NO20005128L (en) |
| PL (1) | PL343482A1 (en) |
| SK (1) | SK15442000A3 (en) |
| TR (1) | TR200002894T2 (en) |
| WO (1) | WO1999053921A1 (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8252309B2 (en) | 2000-04-04 | 2012-08-28 | Sigma-Tau Industrie Farmaceutiche Riunite Spa | Dietary supplement energy-providing to skeletal muscles |
| DE10326822A1 (en) * | 2003-06-11 | 2005-01-05 | Herzpharma Vita-Check Diagnosegeräte GmbH | Dietary supplement, e.g. for increasing general performance, concentration and endurance, comprises NADH, L-carnitine, coenzyme Q10, L-carnosine, succinic acid, ascorbic acid and bioflavonoids |
| AU2007353211B2 (en) * | 2007-05-11 | 2013-08-29 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Gel useful for the delivery of cosmetic active ingredients |
| WO2011022786A1 (en) * | 2009-08-31 | 2011-03-03 | Pharmaqest Pty Ltd | Methods for diagnosis and treatment of chronic fatigue syndrome |
| CN104306390A (en) * | 2014-10-23 | 2015-01-28 | 苏州人本药业有限公司 | Application of reduced coenzyme II |
| CN104840479A (en) * | 2015-02-17 | 2015-08-19 | 苏州人本药业有限公司 | Application of NADPH in preparation of drugs used for treating heart diseases |
| US10894059B2 (en) * | 2017-12-22 | 2021-01-19 | Bontac Bio-Engineering (Shenzhen) Co., Ltd | NADH compound composition, and preparation and use thereof |
| EP3755160B1 (en) | 2018-04-20 | 2021-11-03 | Pacotrade AG | Device for crushing deep-frozen foodstuffs provided in block form |
| CN109170907A (en) * | 2018-08-30 | 2019-01-11 | 泓博元生命科技（深圳）有限公司 | A kind of preparation method of composition containing NMN, application and sports drink |
| CN109105702A (en) * | 2018-08-30 | 2019-01-01 | 泓博元生命科技（深圳）有限公司 | A kind of preparation method of composition containing NADH, application and energy extender |
| JP7199518B2 (en) * | 2018-10-10 | 2023-01-05 | 蘇娥 梁 | Health care product composition for deficit compensation, method of making and use thereof |
| CN117958433A (en) * | 2024-03-22 | 2024-05-03 | 四川新渔新美健康科技有限公司 | Caffeine-free anti-fatigue functional composition and beverage |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1054698A (en) * | 1964-12-04 | |||
| US5292538A (en) * | 1992-07-22 | 1994-03-08 | Metagenics, Inc. | Improved sustained energy and anabolic composition and method of making |
| DE4335454A1 (en) * | 1993-10-19 | 1995-04-20 | Schleicher Peter | Geriatric medical composition |
| JPH09110708A (en) * | 1995-08-11 | 1997-04-28 | Taisho Pharmaceut Co Ltd | Nutritional tonic crude drug combination preparation |
| JPH0959161A (en) * | 1995-08-23 | 1997-03-04 | Taisho Pharmaceut Co Ltd | Fatigue improving composition |
| IT1277953B1 (en) * | 1995-12-21 | 1997-11-12 | Sigma Tau Ind Farmaceuti | PHARMACEUTICAL COMPOSITION CONTAINING L-CARNITINE OR AN ALCANOYL L-CARNITINE AND A 3-OMEGA SERIES POLYUNSATURED ACID USEFUL |
| IT1283951B1 (en) * | 1996-03-15 | 1998-05-07 | Mendes Srl | USE OF ACETYL L-CARNITINE OR ITS PHARMACOLOGICALLY ACCEPTABLE SALTS FOR THERAPEUTIC TREATMENT OR PROPHYLAXIS OF |
| US5712259A (en) * | 1996-04-22 | 1998-01-27 | Birkmayer Pharmaceuticals | NADH and NADPH pharmaceuticals for treating chronic fatigue syndrome |
| US6077828A (en) * | 1996-04-25 | 2000-06-20 | Abbott Laboratories | Method for the prevention and treatment of cachexia and anorexia |
| JPH10175856A (en) * | 1996-10-14 | 1998-06-30 | Taisho Pharmaceut Co Ltd | Fatigue improver |
-
1998
- 1998-04-17 IT IT98RM000238A patent/IT1299161B1/en active IP Right Grant
-
1999
- 1999-04-14 WO PCT/IT1999/000088 patent/WO1999053921A1/en not_active Ceased
- 1999-04-14 TR TR2000/02894T patent/TR200002894T2/en unknown
- 1999-04-14 CA CA002328331A patent/CA2328331A1/en not_active Abandoned
- 1999-04-14 EP EP99916039A patent/EP1071424A1/en not_active Withdrawn
- 1999-04-14 AU AU34428/99A patent/AU750645B2/en not_active Ceased
- 1999-04-14 JP JP2000544325A patent/JP2002512191A/en active Pending
- 1999-04-14 SK SK1544-2000A patent/SK15442000A3/en unknown
- 1999-04-14 PL PL99343482A patent/PL343482A1/en not_active Application Discontinuation
- 1999-04-14 HU HU0101914A patent/HUP0101914A3/en unknown
- 1999-04-14 KR KR1020007011499A patent/KR20010042765A/en not_active Withdrawn
- 1999-04-14 IL IL13901499A patent/IL139014A0/en unknown
- 1999-04-14 BR BR9909712-5A patent/BR9909712A/en not_active IP Right Cessation
- 1999-04-14 CN CN99805644A patent/CN1299283A/en active Pending
- 1999-04-14 EE EEP200000601A patent/EE200000601A/en unknown
-
2000
- 2000-10-12 NO NO20005128A patent/NO20005128L/en not_active Application Discontinuation
- 2000-10-13 IS IS5663A patent/IS5663A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR9909712A (en) | 2000-12-26 |
| HUP0101914A2 (en) | 2002-03-28 |
| ITRM980238A1 (en) | 1999-10-17 |
| IL139014A0 (en) | 2001-11-25 |
| IT1299161B1 (en) | 2000-02-29 |
| AU750645B2 (en) | 2002-07-25 |
| AU3442899A (en) | 1999-11-08 |
| SK15442000A3 (en) | 2001-06-11 |
| CN1299283A (en) | 2001-06-13 |
| PL343482A1 (en) | 2001-08-27 |
| NO20005128L (en) | 2000-12-18 |
| NO20005128D0 (en) | 2000-10-12 |
| HUP0101914A3 (en) | 2002-12-28 |
| IS5663A (en) | 2000-10-13 |
| EE200000601A (en) | 2002-04-15 |
| JP2002512191A (en) | 2002-04-23 |
| CA2328331A1 (en) | 1999-10-28 |
| EP1071424A1 (en) | 2001-01-31 |
| WO1999053921A1 (en) | 1999-10-28 |
| KR20010042765A (en) | 2001-05-25 |
| ITRM980238A0 (en) | 1998-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR052921A1 (en) | USE OF RANOLAZINE FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION AND PHARMACEUTICAL COMPOSITION | |
| TR200002894T2 (en) | L-Carnitine or an alkanoyl L-Carnitine and composition containing NADH and / or NADPH | |
| WO2003013549A3 (en) | Formulation containing (lyso-) phosphatidylserine for the prevention and treatment of stress states in warm-blooded animals | |
| BR9710585A (en) | Composition for enteral administration, process to improve the physical resistance or athletic performance of a mammal, to increase the concentration of protein, fat-free body mass or muscle mass in a mammal, to decrease the deposition of body fat for a given caloric intake and to increase the loss of body fat in a mammal, to treat the catabolic effects of disease in a mammal, to improve a mammal's physical endurance or athletic performance, and to increase the mass of a mammal's lean body and decrease the fat deposition | |
| IL108285A0 (en) | Use of riluzole for the treatment of parkinson's disease and parkinsonian syndromes | |
| PT1163904E (en) | COMPOSITION FOR THE PREVENTION OF SMOOTH MUSCLE DISEASES, COMPOSING ASCORBATE, ARGININE AND MAGNESIUM | |
| PE20001325A1 (en) | CERIVASTATIN AND FIBRATES COMBINATION | |
| CA2377128A1 (en) | Composition for the prevention of muscle fatigue and skeletal muscle adaptation to strenuous exercise | |
| ATE366106T1 (en) | COMPOSITION FOR PHARMACEUTICAL OR DIETARY USE TO COMBAT HAIR LOSS | |
| HUP9700806A2 (en) | Matrix tablet allowing the prolonged release of the sodium salt of tianeptine and process for the preparation thereof | |
| IT1295408B1 (en) | ASSOCIATION OF L-CARNITINE AND ALCANOYL L-CARNITINE FOR THE TREATMENT OF ALCOHOLISM | |
| BRPI0409699A (en) | methods of inducing the diuretic effect, inducing, maintaining or restoring the diuretic effect of a non-adenosine modifying diuretic, maintaining, restoring or improving renal function in a patient, inducing diuresis, preventing the onset of renal impairment in a patient with fluid or CHF overload, treating CHF patients and improving overall health outcomes, pharmaceutical composition and uses | |
| MX9703810A (en) | Medicament comprising a carnitine derivative to treat alzheimer disease in patients with premature onset. | |
| BR9813856A (en) | Processes for the treatment of a patient suffering from premenstrual syndrome, depression, anemia, migraines or eating disorders and to increase the level of serotonin in a human with a reduced level of blood flow and composition | |
| ATE261733T1 (en) | COMPOSITION OF GINSENG AND GINKGO TO IMPROVE COGNITIVE ABILITY | |
| BR0108261A (en) | Use of mirtazapine, method of treating a sleep disorder in an individual, and patient kit for the treatment of sleep disorders | |
| ES1052893U (en) | Balancing instrument gymnastics. (Machine-translation by Google Translate, not legally binding) | |
| CN2836786Y (en) | The vola acupressure probe | |
| Burns et al. | Acute Effects Of Whole-body Vibration And Bicycle Ergometry On Muscular Strength And Flexibility: 1344: Board# 199: 3: 30 PM-5: 00 PM | |
| HUP9701606A2 (en) | Use of sulbutiamine to obtain pharmaceutical compositions useful in the treatment of certain psychomotor and psychointellectual disorders | |
| Inoue et al. | Increased Serum Irisin Level By Aerobic Training Is Involved In NO Production In Obese Rats: 2254 Board# 90 June 1 11: 00 AM-12: 30 PM | |
| BR0303384A (en) | Citalopram And Its Uses In The Treatment Of High Blood Pressure | |
| Webster et al. | The chief scientist reports... hyperbaric oxygen for multiple sclerosis patients | |
| Johnson | Ephedra and Ma Huang Consumption: Do the Benefits Outweigh the Risks? | |
| Matheson | Are We Losing the Injury-Prevention Battle? |